Upstream Bio, Inc.

NasdaqGS:UPB Stock Report

Market Cap: US$437.0m

Upstream Bio Future Growth

Future criteria checks 2/6

Upstream Bio's earnings are forecast to decline at 11.6% per annum while its annual revenue is expected to grow at 62.6% per year. EPS is expected to decline by 2.9% per annum.

Key information

-11.6%

Earnings growth rate

-2.90%

EPS growth rate

Biotechs earnings growth25.5%
Revenue growth rate62.6%
Future return on equityn/a
Analyst coverage

Good

Last updated19 May 2026

Recent future growth updates

Recent updates

Seeking Alpha • Feb 12

Upstream Bio: Hold Rating As Verekitug Faces Competition Among Latest Asthma Data

Summary Upstream Bio, Inc. is downgraded to Hold despite positive phase 2 VALIANT results for Verekitug in severe asthma. Verekitug achieved a 56% AAER reduction at 100 mg Q12W and 39% at 400 mg Q24W, offering competitive dosing versus Tezspire. Competitive threats loom as multiple companies pursue long-acting anti-TSLP antibodies with potentially superior efficacy and less frequent dosing. UPB remains well-capitalized through 2027, but future value hinges on rival data and regulatory outcomes for phase 3 advancement. Read the full article on Seeking Alpha
Analysis Article • Jul 27

Upstream Bio (NASDAQ:UPB) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • Apr 17

Upstream Bio: Verekitug, A Longer-Acting Dupixent? - Key Data Is Imminent

Summary Upstream Bio's IPO raised ~$293m, focusing on developing verekitug, a unique TSLP receptor antagonist for severe respiratory disorders, now in Phase 2 trials. The company has a strong cash position of $471m, despite a net loss of $63m in 2024, providing a long funding runway. Verekitug's less frequent dosing and good safety profile offer potential advantages, but its success hinges on upcoming Phase 2 data readouts. Given the competitive market and high failure rates in clinical studies, investors should be aware that Upstream must be considered a higher risk investment. Nevertheless, I'm "sticking my neck out" and suggesting the stock merits a "Buy" recommendation, ahead of Chronic rhinosinusitis data due before the end of this year. Read the full article on Seeking Alpha
Analysis Article • Apr 12

We Think Upstream Bio (NASDAQ:UPB) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • Dec 16

Upstream Bio: Treating Respiratory Disorders With TSLP Targeting Differentiation

Summary Upstream Bio, Inc. raised approximately $293 million in an IPO, positioning it to leverage upstream pathway targeting of TSLP for treatment of patients with respiratory disorders using verekitug. Release of results from the phase 2 study, using verekitug for the treatment of patients with Chronic Rhinosinusitis with Nasal Polyps, expected to be released in the 2nd half of 2025. The global Chronic Rhinosinusitis market is expected to reach $3.5 billion by 2027. Other catalysts are phase 2 study data using verekitug for Severe Asthma and initiation of mid-stage study for COPD, expected 2nd half 2026 and 2nd half 2025 respectively. Read the full article on Seeking Alpha
Seeking Alpha • Dec 07

Upstream Bio: Attractive, But Let's Wait For More Data And Lock-Up Expiry

Summary Upstream Bio's sole drug, verekitug, targets severe asthma, CRSwNP, and COPD, with promising early phase 2 data expected in 2025 and 2026. Verekitug, a TSLP receptor inhibitor, shows higher efficacy in reducing FeNO and eosinophils compared to competitors like Tezepelumab, Dupilumab, and Mepolizumab. With a market cap of $1.18bn and $220.7 million in cash, UPB has a cash runway through 2027, despite high valuation risks. I find UPB attractive but will wait for phase 2 data and the lock-up period to expire before considering an investment. Read the full article on Seeking Alpha

Earnings and Revenue Growth Forecasts

NasdaqGS:UPB - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20285-274-298N/A5
12/31/20272-209-176-1566
12/31/20262-172-161-1657
3/31/20263-157-140-140N/A
12/31/20253-143-133-133N/A
9/30/20253-136-123-122N/A
6/30/20253-110-115-114N/A
3/31/20252-90-83-83N/A
12/31/20242-76-60-59N/A
9/30/20242-57-56-56N/A
6/30/20242-47-47-47N/A
3/31/20242-44-47-47N/A
12/31/20232-38-38-38N/A
12/31/20221-24-19-19N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: UPB is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: UPB is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: UPB is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: UPB's revenue (62.6% per year) is forecast to grow faster than the US market (11.6% per year).

High Growth Revenue: UPB's revenue (62.6% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if UPB's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/20 04:54
End of Day Share Price 2026/05/20 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Upstream Bio, Inc. is covered by 7 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Cory KasimovEvercore ISI
Tessa RomeroJ.P. Morgan
Joseph CatanzaroMizuho Securities USA LLC